Pfizer (NYSE: PFE) announced Tuesday it plans to sell roughly 700M ordinary shares in Haleon (NYSE: HLN) to lower its stake in the British consumer healthcare giant from about 15.0% to 7.3% ...

Pfizer (NYSE: PFE) has generated £2.5B ($3.24B) after selling its entire stake in Haleon (NYSE: HLN), the consumer healthcare company it established with the British pharmaceutical giant GSK (GSK ...

As a result, Pfizer will reduce its holding in Haleon to around 15% from around 22.6%. The settlement of both operations is expected to occur on Thursday, subject to certain conditions.

Pfizer also sold around £170 million worth of shares back to Haleon in an off-market share repurchase transaction. Haleon shares were down 0.2% as of 8:38 a.m. in London on March 19 after ...

Haleon, known for products like Sensodyne toothpaste and Panadol painkillers, saw its shares drop 1.2% to 388 pence in Tuesday morning trade. Despite the sale, Pfizer remains Haleon’s largest ...

Pfizer will receive all of the net proceeds, while Haleon won't receive any. Write to Najat Kantouar at [email protected] (END) Dow Jones Newswires January 14, 2025 12:16 ET (17:16 GMT) ...

The transaction, which occurred on Monday, reduced Pfizer's shareholding from 22.6% to 15%. The shares were sold at 380 pence each, a 3.3% discount compared to Haleon's last closing price.

(Reuters) -Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding in the maker of Sensodyne toothpaste and Panadol and Advil ...

Sensodyne, the toothpaste first marketed in 1961 to reduce the pain of sensitive teeth, is among premium brands on sale in pharmacies and drug stores around the world. But if you live in an Indian ...

Pfizer will sell about 662 million ordinary shares, or 7.3%, of Haleon, created in a merger of GSK and Pfizer's consumer healthcare businesses in 2019, and spun off in 2022.

Pfizer will receive around 2.66 billion pounds ($3.56 billion) in aggregate from Haleon from an offering and a share buyback. Goldman Sachs International said Tuesday that the pharmaceutical ...